A Chimeric Virus-Mouse Model System for Evaluating the Function and Inhibition of Papain-Like Proteases of Emerging Coronaviruses by Xufang Deng et al.
A Chimeric Virus-Mouse Model System for Evaluating the Function
and Inhibition of Papain-Like Proteases of Emerging Coronaviruses
Xufang Deng,a Sudhakar Agnihothram,b Anna M. Mielech,a Daniel B. Nichols,a Michael W. Wilson,c Sarah E. St. John,d
Scott D. Larsen,c Andrew D. Mesecar,d Deborah J. Lenschow,e Ralph S. Baric,b Susan C. Bakera
Department of Microbiology and Immunology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USAa; Departments of Epidemiology and
Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USAb; Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of
Michigan, Ann Arbor, Michigan, USAc; Departments of Biological Science and Chemistry, Purdue University, West Lafayette, Indiana, USAd; Department of Internal
Medicine and Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USAe
ABSTRACT
To combat emerging coronaviruses, developing safe and efficient platforms to evaluate viral protease activities and the efficacy of
protease inhibitors is a high priority. Here, we exploit a biosafety level 2 (BSL-2) chimeric Sindbis virus system to evaluate pro-
tease activities and the efficacy of inhibitors directed against the papain-like protease (PLpro) of severe acute respiratory syn-
drome coronavirus (SARS-CoV), a biosafety level 3 (BSL-3) pathogen.We engineered Sindbis virus to coexpress PLpro and a
substrate, murine interferon-stimulated gene 15 (ISG15), and found that PLpro mediates removal of ISG15 (deISGylation) from
cellular proteins. Mutation of the catalytic cysteine residue of PLpro or addition of a PLpro inhibitor blocked deISGylation in
virus-infected cells. Thus, deISGylation is a marker of PLpro activity. Infection of alpha/beta interferon receptor knockout
(IFNAR/) mice with these chimeric viruses revealed that PLpro deISGylation activity removed ISG15-mediated protection
during viral infection. Importantly, administration of a PLpro inhibitor protected these mice from lethal infection, demonstrat-
ing the efficacy of a coronavirus protease inhibitor in a mouse model. However, this PLpro inhibitor was not sufficient to protect
the mice from lethal infection with SARS-CoVMA15, suggesting that further optimization of the delivery and stability of PLpro
inhibitors is needed.We extended the chimeric-virus platform to evaluate the papain-like protease/deISGylating activity of Mid-
dle East respiratory syndrome coronavirus (MERS-CoV) to provide a small-animal model to evaluate PLpro inhibitors of this
recently emerged pathogen. This platform has the potential to be universally adaptable to other viral and cellular enzymes that
have deISGylating activities.
IMPORTANCE
Evaluating viral protease inhibitors in a small-animal model is a critical step in the path toward antiviral drug development. We
modified a biosafety level 2 chimeric virus system to facilitate evaluation of inhibitors directed against highly pathogenic corona-
viruses. We used this system to demonstrate the in vivo efficacy of an inhibitor of the papain-like protease of severe acute respi-
ratory syndrome coronavirus. Furthermore, we demonstrate that the chimeric-virus system can be adapted to study the pro-
teases of emerging human pathogens, such as Middle East respiratory syndrome coronavirus. This system provides an important
tool to rapidly assess the efficacy of protease inhibitors targeting existing and emerging human pathogens, as well as other en-
zymes capable of removing ISG15 from cellular proteins.
Emerging coronaviruses (CoVs) are now recognized for theirlife-threatening potential. The outbreak of severe acute respi-
ratory syndrome coronavirus (SARS-CoV) that occurred a decade
ago resulted in over 8,000 infected people, with 10%mortality (1).
A recently emerged coronavirus, designated Middle East respira-
tory syndrome coronavirus (MERS-CoV), has infected over 837
people, with 291 deaths as of 24 July 2014 (http://www.who.int/csr
/don/2014_07_23_mers/en/). Epidemiologic studies implicate
animal reservoirs as the source for emerging coronaviruses. By
identifying a SARS-like CoV from Chinese horseshoe bats and
analyzing the mutations in the spike glycoprotein, first in inter-
mediate hosts and then in humans, researchers were able to doc-
ument the evolution of an emergingCoV (2). The footprint for the
evolution of MERS-CoV is not yet clear. MERS-CoV has about
80% genome sequence identity to the bat coronaviruses HKU4
and HKU5 (3, 4). In addition, infectious MERS-CoV has been
isolated from the respiratory tracts of young camels (5–7), and
there is accumulating evidence that adult camels have specific an-
tibodies to MERS-CoV, consistent with endemic infection in the
camel population (8, 9). Currently, it is unclear if the human cases
of MERS are from sporadic introduction from animal reservoirs
with limited human-to-human transmission or if there is ongoing
transmission ofMERS-CoV in asymptomatic humans or interme-
diate hosts (10–12). It is clear that CoVs have zoonotic potential
for crossing the species barrier and emerging in the human pop-
ulation to cause lethal disease.
Viral proteases are logical targets for antiviral drug develop-
ment, and protease inhibitors have been identified to block the
papain-like protease (PLpro) domain of SARS-CoV (13). PLpro is
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encoded in the viral replicase polyprotein and is critical for pro-
cessing the polyprotein to generate a functional replicase complex.
Structural and enzymatic studies revealed that PLpro is also a viral
deubiquitinase (DUB) that can cleave ubiquitin (Ub) or ubiqui-
tin-likemolecules, such as interferon-stimulated gene 15 (ISG15),
from substrate proteins (14–16). Moreover, the catalysis-depen-
dent interferon antagonism of PLpro implies that it may be in-
volved in evading host innate immunity (17, 18). High-through-
put screening efforts led to the identification of small-molecule
inhibitors directed against the viral papain-like protease domain,
and syntheticmedicinal chemistry and structure-activity relation-
ship studies have produced compounds that inhibit replication of
SARS-CoV in cell culture (13, 19). However, one of the challenges
for preclinical antiviral drug development is the availability of a
small-animalmodel for emergingCoVs. For SARS-CoV, infection
of mouse-adapted strains in mice (20, 21) or transgenic mice ex-
pressing the receptor (angiotensin-converting enzyme 2 [ACE2])
(22, 23) may serve as model systems for evaluating the efficacy of
therapeutics. However, these studies must be performed in bio-
safety level 3 (BSL-3) laboratories with select-agent status. For
MERS-CoV, although rhesus macaques can be infected (24, 25),
less expensive animal models, such as mice and hamsters, are not
susceptible to natural infection (26, 27). Dipeptidyl peptidase 4
(DPP4) was identified as the receptor for MERS-CoV in human
and bat cells (28). Recently, novel model systems were generated
for MERS-CoV infection by infecting mice with recombinant ad-
enovirus expressing the human DPP4 receptor, which renders
them susceptible to infection under BSL-3 conditions (29), and by
generating recombinant HKU5 expressing the SARS-CoV spike
protein (30). Development of additional affordable and adaptable
small-animal models is needed to evaluate antivirals against exist-
ing and potentially emerging coronaviruses.
The goal of our study was to develop a biosafety level 2 system
to evaluate inhibitors of the papain-like proteases of highly patho-
genic emerging coronaviruses, such as SARS-CoV and MERS-
CoV. We were inspired by the fundamental work of Frias-Staheli
et al., who first demonstrated that a chimeric Sindbis virus (SV)
system could be used to evaluate the potential protease activity of
a BSL-4 pathogen, Crimean Congo hemorrhagic fever virus
(CCHFV) (31). This chimeric-virus system is based on the use of
the positive-strandRNAvirus SV, a BSL-2 pathogen that is rapidly
cleared by the immune system after infection in mice. Lenschow
and coworkers showed that the interferon response, particularly
ISG15, is critical for efficient clearance of SV (32). Consequently,
SV infection of interferon receptor knockout (IFNAR/) mice,
which are unable to signal the induction of interferon-stimulated
genes, results in a lethal infection. However, if the gene for ISG15
is inserted into and expressed by SV, then infection with the chi-
meric virus induces an antiviral state andmice are protected from
lethal infection. To induce the antiviral state, ISG15 must be con-
jugated to host cell proteins, a process termed ISGylation (33).
The removal of ISG15 by deISGylating enzymes, such as the L
protease of CCHFV, results in the abrogation of the protection
mediated by ISG15, and mice succumb to infection. Thus,
deISGylating enzymes can be used to “toggle off” the effect of
ISG15 in this system. Given that the PLpros of CoVs not only
function to process the viral polyprotein, but also possess
deISGylating activity (14,34),wereasoned that thechimericSindbis-
ISG15-protease system could be exploited as a surrogate system to
evaluate enzymatic activity and inhibition of CoV PLpros. Here, we
demonstrate the utility of the chimeric SIP system for evaluating the
deISGylating activities of PLpros from SARS-CoV and MERS-CoV
and the efficacy of a SARS-CoV PLpro inhibitor.
MATERIALS AND METHODS
Cells, virus, and plasmids.Ababy hamster kidney cell line (BHK-21) and
Vero-E6 cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) containing 10% (vol/vol) fetal calf serum (FCS) and supple-
mented with penicillin (100 U/ml) and streptomycin (100g/ml). Stocks
of the recombinantmouse-adapted SARS-CoV (rMA15)were propagated
and titrated on Vero-E6 cells. The virus was cryopreserved at80°C until
use, as described below. pcDNA3–6myc-mISG15 was kindly provided
by Min-Jung Kim (Pohang University of Science and Technology, Po-
hang, Republic of Korea). pcDNA3-Ube1L, pcDNA3-UbcH8, and
pcDNA3-Herc5 were kind gifts from Robert M. Krug (University of
Texas). pcDNA-MERS-PLpro and its catalytic mutant (C1592A) were
generated in our laboratory as described previously (35).
PLpro inhibitors 3e and 3h. The synthesis and characterization of
PLpro inhibitors 3e and 3h were described by Baez-Santos et al. (36). For
mouse administration, inhibitor 3e was formulated with 5% dimethyl
sulfoxide (DMSO), 25% polyethylene glycol 400 (PEG 400), and 70%
phosphate-buffered saline (PBS) (vol/vol/vol).
SIP viruses.The Sindbis virus vector dsTE12Qwas kindly provided by
Deborah Lenschow (Washington University, St. Louis, MO). To generate
the chimeric Sindbis virus expressing ISG15 and PLpro, the DNA frag-
ment of ISG15-IRES-PLpro comprising the murine ISG15 cDNA (nucle-
otides [nt] 1 to 465), the hepatitis C virus (HCV) internal ribosome entry
site (IRES) (nt 40 to 371 of the genome of HCV genotype 2b), and PLpro
in frame with a V5 epitope tag at the C terminus (available upon request)
were generated by synthesis or two-step overlapping PCR and subse-
quently cloned into the BstEII restriction site of the dsTE12Q vector. The
insert DNAs of each chimeric virus were generated as follows.
(i) SIP-SWT and SIP-SMT. A DNA sequence comprising the ISG15-
IRES-PLpro (amino acids 1599 to 1855 in pp1a of SARS-CoV) in frame
with a V5 epitope tag was codon optimized, synthesized, and subcloned
into the pUC57 vector (Genscript, NJ). A catalytically inactive mutant of
PLpro (cysteine 1651 to alanine) was generated as described previously
(18) by site-directed mutagenesis PCR using primers (available upon re-
quest). The DNAs of interest were cut from recombinant pUC57 plas-
mids, cloned into the TE12Q vector, and designated SIP-SWT and SIP-
SMT (see below).
(ii) SIP-MWT and SIP-MMT. A DNA sequence comprising ISG15-
IRES-PLpro (amino acids 1483 to 1802 in pp1a of MERS-CoV) was gen-
erated by two-step overlapping PCR using primers (available upon re-
quest). Briefly, the fragment of ISG15-IRES was amplified from the
recombinant pUC57 plasmid described above, and the fragment of
MERS-CoV PLpro or its catalytic mutant in frame with the V5 epitope
was amplified from the plasmids of pcDNA-MERS-PLpro or its catalytic
mutant (cysteine 1592 to alanine), respectively. The fragment of ISG15-
IRES-PLpro was generated by PCR amplification using primers (available
upon request), cloned into the BstE II restriction site of the TE12Q vector,
and designated SIP-MWT and SIP-MMT (see below).
All constructs were verified by sequencing and linearized by digestion
with XhoI restriction enzyme. The viral RNA was synthesized by in vitro
transcription reaction following the manufacturer’s instructions (Am-
bion), and the RNA was subsequently electroporated into BHK-21 cells
with 3 pulses under conditions of 850 V and 25F in a 0.4-cm cuvette cap
(Bio-Rad). Viral supernatants were harvested at 16 to 24 h postelectropo-
ration, and the titers were determined by standard plaque assay on the
BHK-21 cells.
Western blotting. Cell lysates were separated in an SDS-10% PAGE
gel and transferred to a polyvinylidene difluoride (PVDF) membrane in
transfer buffer (25mMTris, 192mMglycine, 20%methanol) for 1 h at 65
V. The membrane was blocked using 5% dried skim milk in TBST buffer
(0.9% NaCl, 10 mM Tris-HCl, pH 7.5, 0.1% Tween 20) for 2 h at room
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temperature and subsequently incubated with primary antibodies over-
night at 4°C. The mouse anti-myc tag monoclonal antibody (MBL) was
used to detect myc-ISG15 and the ISGylated proteins. ISG15 was detected
using rabbit anti-ISG15 polyclonal antibodies (a kind gift from the Len-
schow laboratory). The expression of PLpro and -actin was detected
using mouse anti-V5 (Invitrogen) and anti-beta-actin (Ambion) mono-
clonal antibodies, respectively. Horseradish peroxidase (HRP)-conju-
gated goat anti-mouse (Southern Biotechnology) was used as the second-
ary antibody, detected by using Western Lighting Chemiluminescence
Reagent Plus (PerkinElmer), and visualized using a FluoroChemE imager
(ProteinSimple).
Viral growth kinetics. To analyze the replication of SIP viruses, viral
growth kinetics assays were performed. Briefly, 105 BHK-21 cells per well
in a 24-well plate were infected with each SIP virus at a multiplicity of
infection (MOI) of 5, and the cell supernatants were collected at the indi-
cated time points. The viral titers of the supernatants were determined by
standard plaque assay on the BHK-21 cells.
DeISGylation assay.To determine the deISGylating activity of PLpro,
BHK-21 cells in a 24-well plate were transfected with 0.25 g pcDNA3-
myc-ISG15 and 0.125 g each of ISGylating enzyme expression plasmids
(pcDNA3-Ube1L, pcDNA3-UbcH8, and pcDNA3-Herc5) by Lipo-
fectamine 2000 following the manufacturer’s instructions. At 6 h post-
transfection, themediumwas removed and replaced bymock or SIP virus
inoculumat anMOIof 5. After 1 h of inoculation at 37°C, the inoculawere
replaced by freshDMEMcontaining 1%FCS.Cell lysateswere prepared at
18 h postinfection using 100 l lysis buffer (4% SDS, 3% dithiothreitol
[DTT], and 65 mM Tris, pH 6.8) and analyzed by Western blotting.
To determine the effects of PLpro inhibitors on deISGylating activity,
BHK-21 cells were subjected to transfection and infection as described
above, followed by the addition of fresh DMEM (1% FCS) containing the
inhibitor at a final concentration of 50 M or a serial dilution. After 17 h
of treatment (18 h postinfection), cell lysates were prepared and analyzed
by Western blotting as described above.
Infection of mice with SIP viruses. IFNAR/ mice on a C57BL/6
background were initially obtained from Deborah Lenschow (Washing-
ton University, St. Louis, MO). The mice were bred and maintained at
Loyola University, Chicago, IL, in accordance with all federal and Loyola
University Chicago Institutional Animal Care and Use Committee
(IACUC) guidelines. Seven- to 8-week-old male IFNAR/ mice were
infected subcutaneously in the left hind footpad with 6 106 PFU of SIP
virus diluted in 25 l DMEM, followed by daily body weight monitoring.
When the weight loss of an infected mouse was more than 25% of the
initial body weight, the mouse was humanely euthanized. The survival
rate was calculated by counting the dead or euthanizedmice and analyzed
by log-rank test with GraphPad Prism software.
To determine if the PLpro inhibitor can block the function of PLpro in
vivo, we tested PLpro 3e inhibitor in mice infected with SIP viruses. For
each injection, 50g per dose was administered intraperitoneally (i.p.) at
0 and 2 days postinfection (p.i.). The weight loss of the mice was moni-
tored daily, and the survival rate was analyzed as described above.
Infection of mice with SARS-CoV MA15 virus. All viral and animal
experiments were performed in a class II biological safety cabinet in a
certified biosafety level 3 laboratory containing redundant exhaust fans,
and workers wore personal protective equipment, including Tyvek suits,
hoods, and high-efficiency particle arrestor-filtered powered air-purify-
ing respirators (PAPRs).
Eight-week-old BALB/c mice were purchased from Harlan Laborato-
ries and housed in accordance with all University of North Carolina
(UNC)—Chapel Hill IACUC guidelines. The mice were administered ei-
ther a single dose of 20g poly(I·C) inranasally (i.n.) or 50g per dose of
inhibitor 3e or vehicle i.p. The mice were anesthetized with a mixture of
ketamine-xylazine and were infected i.n. either with 2  104 PFU of the
rMA15 virus or with PBS in a dose of 50 l. Infected animals were mon-
itored daily for weight loss and sacrificed upon approaching 80% of their
starting body weight or manifesting severe clinical symptoms, according
to the IACUC guidelines. The lung tissues of infected mice were collected
at 4 days p.i., and the viral titers were determined by plaque assay on
Vero-E6 cells.
The DNA sequences comprising the ISG15-IRES-PLpro (amino acids
1599 to 1855 in pp1a of SARS-CoV and amino acids 1483 to 1802 in pp1a
ofMERS-CoV) appear in GenBank under accession numbers NP_828849
and AFS88944, respectively.
RESULTS
Exploiting chimeric Sindbis virus to evaluate CoV PLpro activ-
ity. The goal of our study was to establish a BSL-2 mouse model
system to assess the function of CoVPLpros and to evaluate PLpro
inhibitors in vivo. To do this, wemodified a chimeric Sindbis virus
that coexpresses ISG15 and a viral operational taxonomic unit
(OTU) domain deISGylating enzyme (31). To modify the system
to allow expression of the larger ubiquitin-specific protease (USP)
family enzyme from SARS-CoV, we replaced the original en-
cephalomyocarditis virus (EMCV) IRES with the IRES from
HCV. A dicistronic DNA fragment containing ISG15 cDNA fol-
lowed by the HCV IRES and subsequent PLpro coding region was
synthesized and inserted into the BstEII site of the recombinant
Sindbis genome, namely, Sindbis-ISG15-IRES-PLpro (SIP). Four
chimeric Sindbis viruses expressing either wild-type (WT) or cat-
alytic cysteine mutant (MT) PLpros from SARS-CoV andMERS-
CoV were generated and named SIP-SWT, SIP-SMT, SIP-MWT,
and SIP-MMT, respectively (Fig. 1A). The expression of ISG15
andPLprowas detected by immunoblotting lysates prepared from
virus-infected cells (Fig. 1B). Analysis of the viral growth kinetics
revealed that the four SIP viruses replicate with similar kinetics
and to high titer in BHK-21 cells (Fig. 1C). Furthermore, these
viruses were stable upon passage in BHK-21 cells, which was in
contrast to chimeric viruses containing larger insertions that had
an EMCV IRES (data not shown).
PLpros expressed by chimeric Sindbis virus have deISGylat-
ing activity. To determine whether PLpros expressed from Sind-
bis virus are able to cleave ISG15, BHK-21 cells were transfected
with plasmids expressing ISGylation substrates and enzymes
(myc-tagged ISG15, Ube1L, UbcH8, and Herc5) and subse-
quently infected with SIP-WT or SIP-MT viruses. Western blot
results showed that cellular proteins were ISGylated in mock-in-
fected cells transfected with ISGylation machinery plasmids. In
contrast, the level of ISGylated proteins was significantly reduced
in cells infected with SIP-WT, but not SIP-MT, virus (Fig. 2). The
decreased level of ISGylated proteins in SIP-WT-infected cells is
not due to virus-induced cell death or lack of host translation in
the context of a Sindbis virus infection, as the SIP-MT virus grows
to levels similar to those of the SIP-WT virus (Fig. 1C), and cellu-
lar proteins are ISGylated in SIP-MT-infected cells. These results
indicate that both SARS-CoV PLpro and MERS-CoV PLpro ex-
hibit broad deISGylating activity, evenwhen expressed in the con-
text of Sindbis virus infection. These results extend the work of
Frias-Staheli et al. (31) and show that viral USP-type enzymes, like
the viral OTU-type enzyme used in their study, can function as
deISGylating proteases in the context of Sindbis virus infection.
PLpro disrupts ISG15-mediated protection in mice. To de-
termine whether coexpression of PLpro removes the protective
effect of ISG15 during Sindbis virus infection, we infected
IFNAR/mice with SIP-SWT or SIP-SMT virus and monitored
for weight loss and survival. Mice exhibiting greater than 25%
weight loss were humanely euthanized in accordance with animal
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care guidelines. As expected, the mice infected with SIP-SWT vi-
rus lost more body weight thanmice infected with SIP-SMT virus
at days 2 to 5 p.i. (Fig. 3A). SIP-SWT infection results in over 80%
mortality, which is significantly higher than the mortality ob-
served in mice infected with the SIP-SMT virus (26.7%) (P 
0.0005) (Fig. 3B). Moreover, we found that the SIP virus express-
ing wild-type PLpro from MERS-CoV (SIP-MWT), but not the
catalytic inactive cysteine mutant of MERS-CoV PLpro (SIP-
MMT), is able to inhibit the ISG15 function. The weight loss at 4
to 5 days p.i. and the mortality of mice infected with SIP-MWT
were significantly greater than those of SIP-MMT-infected mice
(Fig. 3C and D). These results indicate that PLpros of SARS-CoV
and MERS-CoV are capable of disrupting the ISG15-mediated
protection in IFNAR/mice, suggesting its role in antagonizing
the innate immune response. In our system, the SIP virus-infected
mice approachedmaximumweight loss at 5 to 6 days p.i. and then
either recovered or succumbed to infection, whereas in Frias-
Staheli’s work, the majority of chimeric-virus-infected mice suc-
cumbed to infection at 8 to 12 days p.i. The differential survival
times may due to the different genetic backgrounds of the mouse
strains (129/SV/Pas in their work) or the expression of different
proteases. Next, we wanted to determine if this chimeric Sindbis
virus-mouse system could be used for evaluating small-molecule
inhibitors directed against the PLpro domain.
An inhibitor of SARS-CoVPLpro specifically blocks deISGy-
lating activity. We reported the identification of small-molecule
compounds that block PLpro activity in vitro and block the repli-
cation of SARS-CoV in cell culture (13, 19). We recently designed
and evaluated the biological activity of a second generation of
SARS-CoV PLpro inhibitors in vitro (36). One of these com-
pounds, 3e, inhibits SARS-CoV PLpro with a potency of 390 nM
and has an antiviral potency of 8.3 M against SARS-CoV in
Vero-E6 cells. Importantly, the compound is not cytotoxic, does
not bind to human serum albumin, and has increased metabolic
stability compared to other compounds evaluated (36). There-
fore, to determine if compound 3e blocked PLpro activity in the
context of the chimeric SIP virus, we exploited the deISGylation
assay in cell culture. We found that the cells treated with com-
pound 3e, but not the control compound 3h (Fig. 4A), a structural
homolog of 3e with a higher 50% inhibitory concentration (IC50)
(600 nM) and no antiviral activity (36), showed an increase in the
level of ISGylated proteins in SIP-WT virus-infected cells (Fig.
4B). This indicates that the deISGylating activity of PLpro was
blocked by compound 3e. We also found that the deISGylating
activity of PLpro was inhibited by compound 3e in a dose-depen-
dent manner (data not shown). To assess the specificity of com-
pound 3e, we tested the activity of a cellular deISGylating enzyme,
USP18 (also known asUbp43), in the presence of 3e.Western blot
results revealed that the level of ISGylated proteins in USP18-
transfected cells was significantly decreased compared to the con-
trol, and there was no observable change in the level of ISGylation
FIG 1 Generation of chimeric SIP viruses. (A) Schematic diagram of chimeric
Sindbis viruses expressing ISG15, HCV IRES, and SARS-CoV PLpro (S_
PLpro) or MERS-CoV PLpro (M-PLpro). (B) Detection of PLpro and ISG15
from cells infected with SIP viruses. BHK-21 cells were mock infected or in-
fected with SIP viruses as indicated at anMOI of 5, lysates were prepared at 18
h postinfection, and proteins were detected by immunoblotting. (C) Replica-
tion kinetics of SIP viruses. BHK-21 cells were infected with SIP viruses as
indicated at anMOI of 5, and supernatants were collected at the indicated time
points. The viral titers are representative of three independent experiments.
The error bars represent standard deviations (SD).
FIG 2 PLpros expressed by chimeric Sindbis virus have deISGylating activity.
BHK-21 cells were transfected with ISGylatingmachinery expression plasmids
(myc-ISG15, Ube1L, UbcH8, and Herc5) and subsequently infected with SIP
viruses as indicated. The cell lysates were probed with anti-myc to detect
ISGylated proteins and unconjugated ISG15. The expression of PLpro and
beta-actin as a loading control was detected with anti-V5 and anti-beta-actin
antibodies, respectively.
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in the transfected cells treated with compound 3e (Fig. 4C). This
result indicates that compound 3e does not inhibit the deISGylat-
ing activity of USP18. Taken together, these results suggest that
compound 3e specifically blocks SARS-CoV PLpro deISGylating
activity in cell culture during replication of the SIP virus.
SARS-CoV PLpro inhibitor 3e protects mice from lethal SIP
virus infection. To determine whether the PLpro inhibitor was
effective in a small-animal model, we injected IFNAR/ mice
subcutaneously with SIP-WT and administered compound 3e (50
g/dose) i.p. at 0 and 2 days p.i. Although we found that there was
no significant difference in weight loss between 3e- and vehicle-
treated mice at early time points, except at 5 days p.i. (P 0.01),
themajority of the 3e-treated-mice (64.7%) recovered from infec-
tion before approaching the weight loss leading to euthanasia. In
contrast, SIP-WT-infected mice administered the vehicle control
exhibited significantly higher mortality (31.6% survival rate; P
0.021) (Fig. 5). The effect of compound 3e was specific to SARS-
CoV PLpro activity, as it had no significant effect on the patho-
genesis of Sindbis virus infection of IFNAR/mice and there was
no evidence of weight loss in mice injected with compound 3e
alone (data not shown). These results demonstrate the protective
effect of compound 3e during SIP-WT virus infection.
Evaluation of inhibitor 3e in SARS-CoV MA15-infected
mice. To extend our studies to a respiratory tract model system,
we evaluated 3e using the established SARS-CoV MA15 intrana-
sal-infectionmodel (20). Wild-type BALB/c mice were pretreated
intranasally with a 20-g single dose of poly(I·C) as a positive
control or 1 dose of compound 3e (50g/dose) 4 h prior to infec-
tion. Overall, the mice were administered 50g/dose of 3e twice a
day on days 0 (4 h postinfection), 1, and 2 postinfection, the mice
FIG 4 Compound 3e blocks the deISGylating activity of SARS-CoV PLpro in
cell culture. (A) Structures of tested compounds. (B) BHK-21 cells were trans-
fected with ISGylating machinery plasmids and subsequently infected with
SIP-SWT virus as indicated, followed by addition of 50 M compound 3e or
3h. (C) BHK-21 cells cotransfected with ISGylating machinery plasmids and
USP18 expression plasmids were treated with 50Mcompound 3e or DMSO.
Cell lysates were immunoblotted with anti-myc antibody for detecting the
ISGylated proteins. Expression of PLpro, USP18, and beta-actin as a loading
control was detected with anti-V5, anti-hemagglutinin (HA), and anti-beta-
actin antibodies, respectively.
FIG 3 PLpros inhibit the ISG15-mediated antiviral effect in IFNAR/mice. Seven- to 8-week-old male IFNAR/mice were injected in the footpad with the
WT (SWTorMWT) orMT (SMTorMMT) SIP viruses at 6 106 PFU andmonitored for weight loss. The data are pooled from three independent experiments.
The numbers of mice per group are indicated in parentheses. The statistical differences in body weight loss (A) and survival rate (B) were analyzed using Prism
software with the two-way analysis of variance (ANOVA) test and the log-rank test, respectively. The error bars represent standard errors of the mean (SEM). *,
P 0.05; **, P 0.01; ***, P 0.001.
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were monitored for weight loss through day 4 postinfection, and
virus titers in the lungs were assessed on day 4 postinfection. Mice
treatedwith compound 3ewere not protected from virus-induced
weight loss or virus replication, whereas the poly(I·C)-treated
mice were completely protected from weight loss, and the virus
titers on day 4 showed significant reduction in virus replication
compared to the untreated-virus control (Fig. 6). The results sug-
gest that although protease inhibitor 3e was capable of protecting
the majority of mice from lethal systemic SIP virus infection, the
inhibitor is either not sufficiently stable or bioavailable in the re-
spiratory tract to reduce the replication and pathogenesis of a
respiratory tract infection with SARS-CoV MA15 in mice.
DISCUSSION
This work establishes a chimeric Sindbis virus-mouse model sys-
tem for assessing the deISGylating activity of SARS-CoV and
MERS-CoV PLpros and for evaluating SARS-CoV PLpro inhibi-
tors in BSL-2 containment. To develop this model system, we
exploited a chimeric Sindbis virus system pioneered by Frias-Sta-
heli and coworkers, who first showed that viral proteases with
deISGylating activity could remove the protective antiviral state
induced by ISG15 (31). We extended their studies by (i) modify-
ing the chimeric virus to express either SARS-CoV PLpro or
MERS-CoV PLpro under translational control of the HCV IRES
(this shortened IRES enabled the insertion of larger CoVUSP-like
proteases) and (ii) showing that SARS-CoV PLpro inhibitors
could be evaluated in SIP virus-infected IFNAR/ mice. This is
the first demonstration of the efficacy and specificity of an inhib-
itor that targets a viral papain-like cysteine protease (PLpro) in a
virus-infected animal. This is important because there are over
100 cellular DUBs, and previously, it was unclear if the PLpro
inhibitor was sufficiently specific to alter protease/deISGylating
activity in an infected animal. In general, this chimeric Sindbis
virus-protease system enables the study of enzymes with deISGy-
lating activity and establishes a BSL-2 model that can be used to
evaluate the efficacy of small-molecule inhibitors of existing and
emerging coronaviruses in vivo.
We hypothesize that the multifunctionality of CoV PLpros as
proteases and deubiquitinating and deISGylating enzymes is im-
portant in viral pathogenesis, especially in antagonizing the innate
immune response. ISG15 functions as an antiviral molecule
through ISGylation of host substrates and by eliciting cytokine
activity (36). Mice lacking ISG15 are more susceptible to lethal
infection with Sindbis virus, herpesvirus, and influenza virus (32,
37). The role of ISG15 inCoVpathogenesis is not yet clear.Ma and
coworkers showed that murine coronavirus infection of USP18-
deficient mice, where ISGylation levels are high, resulted in lower
FIG 5 Compound 3e blocks PLpro from disrupting ISG15-mediated protec-
tion in IFNAR/ mice. IFNAR/ mice were infected subcutaneously with
SIP-SWT virus at 0 days p.i. and administered 50 g per mouse of compound
3e or vehicle only i.p. at 0 and 2 days p.i. The mice were monitored for body
weight loss (A) and survival (B). The data are pooled from three independent
experiments. Total mouse numbers per group are indicated in parentheses.
The statistical differences in weight loss and survival were analyzed with Prism
software using the 2-way ANOVA test and the log-rank test, respectively. The
error bars represent SEM. **, P 0.01.
FIG 6 Evaluation of PLpro inhibitor 3e in the SARS-CoV MA15 mouse
model. (A) Five 8-week-old BALB/c mice from each group were administered
either a single dose of 20 g poly(I·C) (Poly IC) i.n. or 50 g per dose of 3e or
vehicle i.p. at 4 h prior to infection i.n. with 2 104 PFU strain MA15 virus.
The infectedmicewere further treatedwith 3e or vehicle twice a day at 0, 1, and
2 days p.i. The mice were monitored for weight loss and mortality. (B) The
viral titer in the lung was determined at 4 days p.i. The statistical differences in
weight loss and titer were analyzed with Prism software using the t test. The
error bars represent SEM.
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viral titers and prolonged survival compared to wild-type mice,
suggesting that high levels of ISGylation may delay CoV replica-
tion and pathogenesis (38). However, USP18 also mediates ISGy-
lation-independent dendritic cell maturation (39), and thus, the
loss of USP18 function may affect the kinetics of the immune
response to viral infection. In the present study, we directly
showed that CoV PLpros are capable of disrupting the protective
effect of ISG15 in vivo, suggesting that PLpros have evolved an
ISGylation antagonism mechanism to promote viral replication.
A major advantage of the SIP virus system is that we were able
to study the PLpros of pathogenic CoVs in mice in a BSL-2 envi-
ronment. This is particularly important because of the limited
number of small-animal models currently available for the study
of MERS-CoV PLpro inhibitors (29, 30). MERS-CoV enters cells
by interaction with DPP4, and both human and bat DPP4s are
functional receptors (28). In contrast, mice and rats are resistant
to infection (26, 27), likely because of differences in the portion of
DPP4 that interacts with the receptor binding domain of the spike
glycoprotein of MERS-CoV (40, 41). The development of mouse-
adapted strains of MERS-CoV and the generation of transgenic
mice expressing the humanDPP4 receptor are aimed at providing
critical tools needed for understanding pathogenesis and evaluat-
ing candidate vaccines, but this work will be performed in BSL-3
containment. In contrast, the SIP virus mouse model is used in
BSL-2 containment, and experiments are cost-effective for evalu-
ating the efficacy and toxicity of PLpro inhibitors. In addition, we
envision expanding the SIP virus system to identify broad-spec-
trum PLpro inhibitors that block a wide array of human and bat
PLpro activities and protectmice from lethal viral infection.Using
the SIP system, we can evaluate the efficacy of an inhibitor of a
novel bat PLpro without the need for developing a transgenic-
mouse model expressing the receptor for the novel virus. An im-
portant caveat of the SIP virus system is that it is a systemic infec-
tion and lethality is due to transmission of the virus through the
central nervous system (32). Thus, it is a very sensitive system for
evaluating protease inhibitors, and we demonstrate the efficacy of
protease inhibitor 3e, which was previously shown to block repli-
cation of SARS-CoV in cell culture (36). However, as we report
here, protease inhibitors must also be evaluated in the context of a
respiratory tract infection, such as with mouse-adapted SARS-
CoV MA15 (20, 21). We found that the protease inhibitor 3e was
not effective at blocking replication and pathogenesis of SARS-
CoV MA15 in the respiratory tracts of infected mice. This lack of
efficacy may be due to the relative instability of 3e (36) or limita-
tions of delivery onto themucosal surfaces of the respiratory tract,
the site of natural infection. Further work is required to optimize
PLpro inhibitors for bioavailability, stability and appropriate de-
livery to block replication and pathogenesis of coronavirus.
Papain-like proteases (PLpros or PLPs) are conserved in all
coronaviruses, and the goal of identifying a broad-spectrum in-
hibitor would be to inhibit existing human and potential emerg-
ing CoVs. Several CoV PLPs have been identified as deISGylating
enzymes, such as the PLpro domain of SARS-CoV (14) and the
PLP2 domain of human coronavirus (HCoV) NL63 (18). The SIP
system described here could be extended to study the function of
the PLpro/PLP2 domain of endemicHCoVs, such asHCoVNL63,
HCoV HKU1, HCoV 229E, and HCoV OC43. HCoV NL63 gen-
erally causes mild upper respiratory tract disease in adults, but it
can cause more severe respiratory disease in young children (42,
43). HCoV-HKU1 has been associated with pneumonia in the
elderly (44). Currently, there are no animal models for evaluating
inhibitors toHCoVNL63 orHCoVHKU1.Other PLPs, including
those of bat coronaviruses, are postulated to act as deISGylating
enzymes, aswell, since they share conserved catalytic elements and
are predicted to recognize similar cleavage sites in the viral poly-
protein. We are currently developing SIP viruses expressing the
PLP2 domain of HCoV NL63 and other CoVs with the long-term
goal of identifying broad-spectrum PLpro inhibitors that could
block replication of existing and emerging coronaviruses.
Overall, this study provides evidence of CoV PLpro deISGylat-
ing activity in the context of viral infection and establishes a BSL-2
mousemodel for evaluating PLpro inhibitors. The current studies
are designed to facilitate antiviral drug development for existing
and emerging coronavirus infections and are a forerunner of the
development of similar platforms aimed at testing inhibitors
against other deISGylating enzymes in vivo.
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